Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-595-2595
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees85
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Atreca (NASDAQ:BCEL) Frequently Asked Questions
What is Atreca's stock symbol?
Atreca trades on the NASDAQ under the ticker symbol "BCEL."
How were Atreca's earnings last quarter?
Atreca (NASDAQ:BCEL) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($3.67) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.77) by $2.89. View Atreca's Earnings History.
When is Atreca's next earnings date?
What price target have analysts set for BCEL?
5 Wall Street analysts have issued twelve-month price objectives for Atreca's stock. Their forecasts range from $16.63 to $28.00. On average, they anticipate Atreca's share price to reach $22.5433 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Price Targets for Atreca.
What is the consensus analysts' recommendation for Atreca?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atreca.
Has Atreca been receiving favorable news coverage?
Media headlines about BCEL stock have been trending positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Atreca earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Atreca.
Who are some of Atreca's key competitors?
Some companies that are related to Atreca include Uniqure (QURE), Zai Lab (ZLAB), Akcea Therapeutics (AKCA), Biohaven Pharmaceutical (BHVN), Cambrex (CBM), Portola Pharmaceuticals (PTLA), Apellis Pharmaceuticals (APLS), Ligand Pharmaceuticals (LGND), Tricida (TCDA), Pacira Biosciences (PCRX), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Nabriva Therapeutics (NBRV) and Corcept Therapeutics (CORT).
What other stocks do shareholders of Atreca own?
Who are Atreca's key executives?
Atreca's management team includes the folowing people:
- Mr. John A. Orwin, Pres, CEO & Director (Age 54)
- Dr. Tito A. Serafini, Co-Founder, Board Member & Chief Strategy Officer (Age 56)
- Mr. Herbert C. Cross, Chief Financial Officer (Age 47)
- Dr. Yann Chong Tan, Chief Technologist
- Dr. Guy Cavet Ph.D., Chief Technical Officer (Age 45)
When did Atreca IPO?
(BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.
When did the company's quiet period expire?
Atreca's quiet period expired on Tuesday, July 30th. Atreca had issued 7,350,000 shares in its IPO on June 20th. The total size of the offering was $124,950,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Who are Atreca's major shareholders?
Atreca's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (6.47%), EcoR1 Capital LLC (5.55%), BlackRock Inc. (3.51%), Samsara BioCapital LLC (2.21%), Cormorant Asset Management LP (1.66%) and Board of Trustees of The Leland Stanford Junior University (1.63%).
Which major investors are buying Atreca stock?
BCEL stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, EcoR1 Capital LLC, BlackRock Inc., Samsara BioCapital LLC, Cormorant Asset Management LP, Board of Trustees of The Leland Stanford Junior University, Aisling Capital Management LP and Monashee Investment Management LLC.
How do I buy shares of Atreca?
Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atreca's stock price today?
One share of BCEL stock can currently be purchased for approximately $21.87.
How big of a company is Atreca?
What is Atreca's official website?
How can I contact Atreca?
Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-595-2595 or via email at [email protected]
MarketBeat Community Rating for Atreca (NASDAQ BCEL)
MarketBeat's community ratings are surveys of what our community members think about Atreca and other stocks. Vote "Outperform" if you believe BCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
